The Fostair® 100/6 (BDP/FF) pressurized metered-dose inhaler, delivering an extrafine formulation, is licensed for asthma and COPD in the UK. However, its real-life effectiveness for COPD has not been evaluated. This study compared the clinical effectiveness of BDP/FF against other licensed ICS/LABA combination inhalers: the Seretide® Accuhaler® (FP/SAL) and the Symbicort® Turbohaler® (BUD/FF).
A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD / Ming, Simon Wan Yau; Haughney, John; Ryan, Dermot; Small, Iain; Lavorini, Federico; Papi, Alberto; Singh, Dave; Halpin, David M G; Hurst, John R; Patel, Shishir; Ochel, Matthias; Kocks, Janwillem; Carter, Victoria; Hardjojo, Antony; Price, David B. - In: INTERNATIONAL JOURNAL OF COPD. - ISSN 1178-2005. - ELETTRONICO. - 15:(2020), pp. 3093-3103-3103. [10.2147/COPD.S263745]
A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD
Lavorini, FedericoMembro del Collaboration Group
;
2020
Abstract
The Fostair® 100/6 (BDP/FF) pressurized metered-dose inhaler, delivering an extrafine formulation, is licensed for asthma and COPD in the UK. However, its real-life effectiveness for COPD has not been evaluated. This study compared the clinical effectiveness of BDP/FF against other licensed ICS/LABA combination inhalers: the Seretide® Accuhaler® (FP/SAL) and the Symbicort® Turbohaler® (BUD/FF).
| File | Dimensione | Formato | |
|---|---|---|---|
|
f_copd-263745-a-comparison-of-the-real-life-clinical-effectiveness-of-the-_64172.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
470.8 kB
Formato
Adobe PDF
|
470.8 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
